Table 1.
Patient Demographics and Baseline Disease Features
| Variable | Regimen | ||
|---|---|---|---|
| CMF | AC | Capecitabine | |
| Patients | 135 (100) | 182 (100) | 302 (100) |
| Age, years | |||
| 65-69 | 36 (27) | 73 (40) | 108 (36) |
| 70-80 | 92 (68) | 102 (56) | 180 (60) |
| ≥ 80 | 7 (5) | 7 (4) | 14 (5) |
| Performance score | |||
| 0 or 1 | 131 (97) | 177 (97) | 290 (96) |
| 2 | 4 (3) | 5 (3) | 12 (4) |
| Race | |||
| White | 117 (87) | 153 (84) | 258 (85) |
| Black | 16 (12) | 25 (14) | 28 (9) |
| Other | 2 (1) | 4 (3) | 16 (6) |
| Receptor | |||
| Both ER/PgR-negative | 43 (32) | 60 (33) | 95 (31) |
| Either ER/PgR-positive | 91 (67) | 122 (67) | 206 (68) |
| Missing | 1 (1) | 0 (0) | 1 (< 1) |
| Tumor size, cm | |||
| ≤ 2 | 68 (50) | 85 (47) | 120 (40) |
| > 2 and ≤ 5 | 57 (42) | 88 (48) | 165 (55) |
| > 5 | 9 (7) | 9 (5) | 17 (6) |
| Missing | 1 (1) | 0 (0) | 0 (0) |
| No. of positive nodes | |||
| 0 | 31 (23) | 58 (32) | 95 (31) |
| 1-3 | 73 (54) | 103 (57) | 154 (51) |
| ≥ 4 | 31 (23) | 20 (11) | 49 (16) |
| Missing | 0 (0) | 1 (1) | 4 (1) |
| Calculated CrCl, mL/min | |||
| ≤ 40 | 27 (20) | 31 (17) | 56 (19) |
| 41-49 | 35 (26) | 45 (25) | 88 (29) |
| 50-59 | 36 (27) | 40 (22) | 82 (27) |
| ≥ 60 | 37 (27) | 66 (36) | 76 (25) |
| Renal function by level | |||
| 1 (normal) | 3 (2) | 5 (3) | 5 (2) |
| 2 (mild) | 34 (25) | 61 (34) | 71 (24) |
| 3 (moderate) | 95 (70) | 112 (62) | 224 (74) |
| 4 (severe) | 3 (2) | 4 (2) | 2 (1) |
| 5 (renal failure) | 0 (0) | 0 (0) | 0 (0) |
| Renal function dichotomized by level | |||
| Level 1 and 2 | 62 (46) | 76 (42) | 144 (48) |
| Level 3 and 4 | 73 (54) | 106 (58) | 158 (52) |
NOTE. Data are given as No. (%) unless otherwise noted.
Abbreviations: AC, cyclophosphamide/doxorubicin; CMF, cyclophosphamide/methotrexate/fluorouracil; CrCl, creatinine clearance; ER, estrogen receptor; PgR, progesterone receptor.